---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-237644"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:59:06.046323+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Neumora Therapeutics closes IPO: 14.71M shares at $17, gross proceeds ~$250.1M

## Summary
- Completed IPO of 14,710,000 shares of common stock at $17.00 per share on September 19, 2023.
- Gross proceeds of approximately $250.1 million before underwriting discounts and expenses.
- Amended and restated certificate of incorporation and bylaws became effective with the IPO.
- Charter provisions include classified board, exclusive forum for derivative and securities claims, and no cumulative voting.

## SEC filing metadata
- accession: 0001193125-23-237644
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/0001193125-23-237644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/d541406d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-237644
- JSON: https://secwatch.observer/filing/0001193125-23-237644.json
- Plain text: https://secwatch.observer/filing/0001193125-23-237644.txt

## Key facts
- Governance Changes
  Neumora Therapeutics, Inc.: Amended and restated bylaws effective upon closing of IPO, including provisions for advance notice, written consent prohibition, director removal, classified board, and forum selection (effective 2023-09-19).
  - Change: bylaw amendment
  - Effective: 2023-09-19
  source text: On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/0001193125-23-237644-index.htm
- Governance Changes
  Neumora Therapeutics, Inc.: Amended and restated certificate of incorporation effective upon closing of IPO, including changes to authorized shares, preferred stock, director election, stockholder action, and forum selection provisions (effective 2023-09-19).
  - Change: charter amendment
  - Effective: 2023-09-19
  source text: On September 19, 2023, Neumora Therapeutics, Inc.’s (the “Company”) amended and restated certificate of incorporation (the “Certificate of Incorporation”), filed with the Secretary of State of the State of Delaware on September 19, 2023, and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1885522/000119312523237644/0001193125-23-237644-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.